Sensitivity and engineered resistance of myeloid leukemia cells to BRD9 inhibition

Nature Chemical Biology

Volumn 12, Issue 9, 2016, Pages 672-679

  Hohmann, Anja F ^a   Martin, Laetitia J ^b   Minder, Jessica L ^a   Roe, Jae Seok ^a   Shi, Junwei ^a,c   Steurer, Steffen ^b   Bader, Gerd ^b   McConnell, Darryl ^b   Pearson, Mark ^b   Gerstberger, Thomas ^b   Gottschamel, Teresa ^b   Thompson, Diane ^b   Suzuki, Yutaka ^d   Koegl, Manfred ^b   Vakoc, Christopher R ^a  

^a Howard Hughes Medical Institute Cold Spring Harbor Laboratory Cold Spring Harbor   (United States)

^b BOEHRINGER INGELHEIM RCV GMBH AND CO KG   (Austria)

^c STONY BROOK UNIVERSITY   (United States)

^d UNIVERSITY OF TOKYO   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BRD9 INHIBITOR; BROMODOMAIN 9 PROTEIN; BROMODOMAIN INHIBITOR; CELL PROTEIN; MYC PROTEIN; PROTEIN SWI; TRANSCRIPTION FACTOR EZH2; TRANSCRIPTION FACTOR SNF; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRD9 PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ACUTE MYELOBLASTIC LEUKEMIA; ALLELE; ANIMAL CELL; ANTIPROLIFERATIVE ACTIVITY; ARTICLE; CANCER RESISTANCE; CELL DIFFERENTIATION; CELL ENGINEERING; CELL PROLIFERATION; CHROMATIN ASSEMBLY AND DISASSEMBLY; DRUG SENSITIVITY; HUMAN; HUMAN CELL; MOUSE; MYELOID LEUKEMIA CELL LINE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; TARGET CELL; ANIMAL; ANTAGONISTS AND INHIBITORS; CHEMICAL STRUCTURE; CHEMISTRY; DOSE RESPONSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENETICS; LEUKEMIA, MYELOID, ACUTE; METABOLISM; MOLECULAR MODEL; PATHOLOGY; STRUCTURE ACTIVITY RELATION;

ALLELES; ANIMALS; ANTINEOPLASTIC AGENTS; CELL DIFFERENTIATION; CELL ENGINEERING; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; DRUG SCREENING ASSAYS, ANTITUMOR; HUMANS; LEUKEMIA, MYELOID, ACUTE; MICE; MODELS, MOLECULAR; MOLECULAR STRUCTURE; STRUCTURE-ACTIVITY RELATIONSHIP; TRANSCRIPTION FACTORS;

EID: 84976874620     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.2115     Document Type: Article

References (53)

1. Schenone, M., Dančík, V., Wagner, B.K. & Clemons, P.A. Target identification and mechanism of action in chemical biology and drug discovery. Nat. Chem. Biol. 9, 232-240 (2013).
2. Blagg, J. & Workman, P. Chemical biology approaches to target validation in cancer. Curr. Opin. Pharmacol. 17, 87-100 (2014).
3. Arrowsmith, C.H. et al. The promise and peril of chemical probes. Nat. Chem. Biol. 11, 536-541 (2015).
4. Titov, D.V. & Liu, J.O. Identification and validation of protein targets of bioactive small molecules. Bioorg. Med. Chem. 20, 1902-1909 (2012).
5. Balzano, D., Santaguida, S., Musacchio, A. & Villa, F. A general framework for inhibitor resistance in protein kinases. Chem. Biol. 18, 966-975 (2011).
6. Filippakopoulos, P. & Knapp, S. The bromodomain interaction module. FEBS Lett. 586, 2692-2704 (2012).
7. Brand, M. et al. Small molecule inhibitors of bromodomain-Acetyl-lysine interactions. ACS Chem. Biol. 10, 22-39 (2015).
8. Filippakopoulos, P. et al. Histone recognition and large-scale structural analysis of the human bromodomain family. Cell 149, 214-231 (2012).
9. Zeng, L. et al. Selective small molecules blocking HIV-1 Tat and coactivator PCAF association. J. Am. Chem. Soc. 127, 2376-2377 (2005).
10. Filippakopoulos, P. et al. Selective inhibition of BET bromodomains. Nature 468, 1067-1073 (2010).
11. Nicodeme, E. et al. Suppression of inflammation by a synthetic histone mimic. Nature 468, 1119-1123 (2010).
12. Suzuki, A. et al. Aberrant transcriptional regulations in cancers: genome, transcriptome and epigenome analysis of lung adenocarcinoma cell lines. Nucleic Acids Res. 42, 13557-13572 (2014).
13. Hay, D.A. et al. Discovery and optimization of small-molecule ligands for the CBP/p300 bromodomains. J. Am. Chem. Soc. 136, 9308-9319 (2014).
14. Chen, P. et al. Discovery and characterization of GSK2801, a selective chemical probe for the bromodomains BAZ2A and BAZ2B. J. Med. Chem. 59, 1410-1424 (2016).
15. Bennett, J. et al. Discovery of a chemical tool inhibitor targeting the bromodomains of TRIM24 and BRPF. J. Med. Chem. 59, 1642-1647 (2016).
16. Shi, J. et al. Role of SWI-SNF in acute leukemia maintenance and enhancer-mediated Myc regulation. Genes Dev. 27, 2648-2662 (2013).
17. Buscarlet, M. et al. Essential role of BRG, the ATPase subunit of BAF chromatin remodeling complexes, in leukemia maintenance. Blood 123, 1720-1728 (2014).
18. Hohmann, A.F. & Vakoc, C.R. A rationale to target the SWI-SNF complex for cancer therapy. Trends Genet. 30, 356-363 (2014).
19. Oike, T. et al. A synthetic lethality-based strategy to treat cancers harboring a genetic deficiency in the chromatin remodeling factor BRG1. Cancer Res. 73, 5508-5518 (2013).
20. Cruickshank, V.A. et al. SWI-SNF subunits SMARCA4, SMARCD2 and DPF2 collaborate in MLL-rearranged leukaemia maintenance. PLoS One 10, e0142806 (2015).
21. Wu, J.I., Lessard, J. & Crabtree, G.R. Understanding the words of chromatin regulation. Cell 136, 200-206 (2009).
22. Vangamudi, B. et al. The SMARCA2/4 ATPase domain surpasses the bromodomain as a drug target in SWI-SNF-mutant cancers: insights from cDNA rescue and PFI-3 inhibitor studies. Cancer Res. 75, 3865-3878 (2015).
23. Kadoch, C. et al. Proteomic and bioinformatic analysis of mammalian SWI-SNF complexes identifies extensive roles in human malignancy. Nat. Genet. 45, 592-601 (2013).
24. Middeljans, E. et al. SS18 together with animal-specific factors defines human BAF-Type SWI-SNF complexes. PLoS One 7, e33834 (2012).
25. Zuber, J. et al. Toolkit for evaluating genes required for proliferation and survival using tetracycline-regulated RNAi. Nat. Biotechnol. 29, 79-83 (2011).
26. Subramanian, A. et al. Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles. Proc. Natl. Acad. Sci. USA 102, 15545-15550 (2005).
27. Dhalluin, C. et al. Structure and ligand of a histone acetyltransferase bromodomain. Nature 399, 491-496 (1999).
28. Zuber, J. et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature 478, 524-528 (2011).
29. Martin, L.J. et al. Structure-based design of an in vivo active selective BRD9 inhibitor. J. Med. Chem. 59, 4462-4475 (2016).
30. Machleidt, T. et al. NanoBRET-A novel BRET platform for the analysis of protein-protein interactions. ACS Chem. Biol. 10, 1797-1804 (2015).
31. Clark, P.G. et al. LP99: discovery and synthesis of the first selective BRD7/9 bromodomain inhibitor. Angew. Chem. Int. Edn Engl. 54, 6217-6221 (2015).
32. Theodoulou, N.H. et al. Discovery of I-BRD9, a selective cell active chemical probe for bromodomain containing protein 9 inhibition. J. Med. Chem. 59, 1425-1439 (2016).
33. McCabe, M.T. & Creasy, C.L. EZH2 as a potential target in cancer therapy. Epigenomics 6, 341-351 (2014).
34. Margueron, R. & Reinberg, D. The Polycomb complex PRC2 and its mark in life. Nature 469, 343-349 (2011).
35. McCabe, M.T. et al. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-Activating mutations. Nature 492, 108-112 (2012).
36. Neff, T. et al. Polycomb repressive complex 2 is required for MLL-AF9 leukemia. Proc. Natl. Acad. Sci. USA 109, 5028-5033 (2012).
37. Kim, W. et al. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer. Nat. Chem. Biol. 9, 643-650 (2013).
38. Winter, G.E. et al. DRUG DEVELOPMENT. Phthalimide conjugation as a strategy for in vivo target protein degradation. Science 348, 1376-1381 (2015).
39. Lu, J. et al. Hijacking the E3 ubiquitin ligase cereblon to efficiently target BRD4. Chem. Biol. 22, 755-763 (2015).
40. Zengerle, M., Chan, K.H. & Ciulli, A. Selective small molecule induced degradation of the BET bromodomain protein BRD4. ACS Chem. Biol. 10, 1770-1777 (2015).
41. Mullard, A. Reliability of new drug target claims called into question. Nat. Rev. Drug Discov. 10, 643-644 (2011).
42. Ross, P.L. et al. Multiplexed protein quantitation in Saccharomyces cerevisiae using amine-reactive isobaric tagging reagents. Mol. Cell. Proteomics 3, 1154-1169 (2004).
43. Gilar, M., Olivova, P., Daly, A.E. & Gebler, J.C. Two-dimensional separation of peptides using RP-RP-HPLC system with different pH in first and second separation dimensions. J. Sep. Sci. 28, 1694-1703 (2005).
44. Wang, Y. et al. Reversed-phase chromatography with multiple fraction concatenation strategy for proteome profiling of human MCF10A cells. Proteomics 11, 2019-2026 (2011).
45. Perkins, D.N., Pappin, D.J., Creasy, D.M. & Cottrell, J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 20, 3551-3567 (1999).
46. Steger, D.J. et al. DOT1L/KMT4 recruitment and H3K79 methylation are ubiquitously coupled with gene transcription in mammalian cells. Mol. Cell. Biol. 28, 2825-2839 (2008).
47. Fellmann, C. et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 5, 1704-1713 (2013).
48. Armour, C.D. et al. Digital transcriptome profiling using selective hexamer priming for cDNA synthesis. Nat. Methods 6, 647-649 (2009).
49. Shi, J. et al. Discovery of cancer drug targets by CRISPR-Cas9 screening of protein domains. Nat. Biotechnol. 33, 661-667 (2015).
50. Vonrhein, C. et al. Data processing and analysis with the autoPROC toolbox. Acta Crystallogr. D Biol. Crystallogr. 67, 293-302 (2011).
51. Collaborative Computational Project, Number 4. The CCP4 suite: programs for protein crystallography. Acta Crystallogr. D Biol. Crystallogr. 50, 760-763 (1994).
52. Emsley, P., Lohkamp, B., Scott, W.G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D Biol. Crystallogr. 66, 486-501 (2010).
53. Chen, V.B. et al. MolProbity: All-Atom structure validation for macromolecular crystallography. Acta Crystallogr. D Biol. Crystallogr. 66, 12-21 (2010)